Express Pharma

DuPont Danisco’s Bifidobacterium lactis HN019 gets recorded with Consumer Affairs Agency, Govt of Japan


Bifidobacterium lactis (HN019) improves defecation for those suffering from constipation by adjusting intestinal environment

Food products containing Bifidobacterium lactis HN019 from the DuPont Danisco range have recently been recorded with the Consumer Affairs Agency, Government of Japan, for Food with Function Claims, further reinforcing the strength of science behind DuPont’s probiotics. HN019 is Bifidobacterium lactis strain which allows a food manufacturer to state a health claim on the product.

Reportedly, food manufacturers who use HN019 in their finished products will now have a more cost effective and efficient way to utilise existing, robust data based on this strain. They will be permitted to print, ‘This product contains Bifidobacterium lactis (HN019). Bifidobacterium lactis (HN019) is reported to improve defecation for those suffering from constipation by adjusting intestinal environment,’ on their packaging levels.

“We are pleased with this newly recorded claim on food products containing HN019,” says Yuta Nakazawa, DS Sales Manager of DuPont Nutrition & Health, Japan. “This is a win-win situation for both our customers and their consumers, especially for small to medium sized companies who do not have their own strains. They can now file for application with the Secretary-General of the Consumer Affairs Agency to include HN019 in their food products which allows them to make function claims on their food labels. This will definitely provide a competitive edge to companies to be better differentiated in the marketplace,” he adds.

Comments are closed.